Oral morphine in cancer pain: influences on morphine and metabolite concentration.
about
Day-to-day variations during clinical drug monitoring of morphine, morphine-3-glucuronide and morphine-6-glucuronide serum concentrations in cancer patients. A prospective observational studyClinically significant drug-drug interactions involving opioid analgesics used for pain treatment in patients with cancer: a systematic reviewBiotransformation and pharmacokinetics of ethylmorphine after a single oral dose.Recent developments in palliative cancer care.The role of morphine glucuronides in cancer pain.A Prospective Population Pharmacokinetic Study on Morphine Metabolism in Cancer PatientsDifferences between opioids: pharmacological, experimental, clinical and economical perspectivesMorphine and morphine-glucuronide concentrations in plasma and CSF during long-term administration of oral morphineEvidence for P-glycoprotein-modulated penetration of morphine-6-glucuronide into brain capillary endothelium.Recent advances in the use of opioids for cancer painThe panorama of opioid-related cognitive dysfunction in patients with cancer: a critical literature appraisal.Influences on the pharmacokinetics of oxycodone: a multicentre cross-sectional study in 439 adult cancer patients.Predicting response to lithium in mood disorders: role of genetic polymorphisms.Anticipating and treating opioid-associated adverse effects.Influence of morphine on pericyte-endothelial interaction: implications for antiangiogenic therapyMorphine, a potential antagonist of cisplatin cytotoxicity, inhibits cisplatin-induced apoptosis and suppression of tumor growth in nasopharyngeal carcinoma xenografts.Oral morphine overdose in a cancer patient antagonized by prolonged naloxone infusion.Variable response to opioid treatment: any genetic predictors within sight?Prevalence of UDP-glucuronosyltransferase polymorphisms (UGT1A6∗2, 1A7∗12, 1A8∗3, 1A9∗3, 2B7∗2, and 2B15∗2) in a Saudi population.Evidence-based medicine: what is the evidence that it has made a difference?A systematic review of the use of opioid medication for those with moderate to severe cancer pain and renal impairment: a European Palliative Care Research Collaborative opioid guidelines project.Plasma concentrations of morphine, morphine-6-glucuronide and morphine-3-glucuronide and their relationship with analgesia and side effects in patients with cancer-related pain.Morphine or oxycodone in cancer pain?Morphine metabolism in neonates and infants.Paradoxical pain.Pain, sedation and morphine metabolism in cancer patients during long-term treatment with sustained-release morphine.A retrospective study of the association between haematological and biochemical parameters and morphine intolerance in patients with cancer pain.
P2860
Q24791044-DAB5E75D-AF13-4F9A-9D90-79CD2BD7F8F4Q26781972-96C76F7E-AE94-46DE-BEFB-06409E985332Q28367979-79EA6A94-663C-4F51-B9C6-8E0183DF3FE3Q33537395-88A0D725-6178-4332-8770-CE816D303A85Q33727191-183D8FFB-18C8-4BAC-9E64-F141A2D4B67EQ33845632-E4724641-7B2D-4A20-87DB-B3636DD5F4D6Q34272502-A53B0DBC-CDCE-4890-9DC0-2D2441BDE132Q34346314-9965E42C-1923-4BB7-B8A5-6AFB91C7A9E6Q34402344-4018DEB0-E8E6-415C-92B3-415F2F65FAD2Q34418203-4653AD79-6A1D-47EF-8100-606E44F8AA04Q34580479-F8372D29-A093-4B4F-A2E7-430700B31F4BQ34792547-0719B701-6646-4A54-9ABF-5BD97F23C6FFQ35058020-4B71E38D-F71B-4F92-A988-3DF0963C81C6Q35194392-EA82BE48-EE06-4C9A-BB90-D36FD3286D29Q35725355-B14115A9-F1B5-4812-B9E0-32D6073D5DAAQ36428066-3CA347A4-B027-4217-98BA-5635F24D0E12Q37186330-ABDC5861-EB59-4353-A33A-4CD18AEF31F5Q37187101-5B4B8D29-D1B3-41DE-8027-A9648CCEEA4CQ37707406-5A70A33B-3FAD-47AD-9442-C70D0E8D4FFEQ37894980-D19FB910-F7F3-4023-A9C4-C791846202DFQ37895002-43D04854-759C-4483-93A5-06AFD1B66750Q39395812-95C8C915-A8D5-4F1D-AFCB-182843EFB022Q39421912-564BB44B-5D83-4604-9104-BC84B4D57900Q43224470-E53A2AAD-C018-4FA2-ADAD-C917BF835CC4Q43719467-117B60D6-03A3-4319-ADEE-C33FE0031327Q43968416-4C34D2DC-0B90-4CF8-9232-21AB4A8BE5D1Q44775521-7C691BC2-A933-4E28-9047-C520BF24F737
P2860
Oral morphine in cancer pain: influences on morphine and metabolite concentration.
description
1990 nî lūn-bûn
@nan
1990年の論文
@ja
1990年論文
@yue
1990年論文
@zh-hant
1990年論文
@zh-hk
1990年論文
@zh-mo
1990年論文
@zh-tw
1990年论文
@wuu
1990年论文
@zh
1990年论文
@zh-cn
name
Oral morphine in cancer pain: influences on morphine and metabolite concentration.
@en
Oral morphine in cancer pain: influences on morphine and metabolite concentration.
@nl
type
label
Oral morphine in cancer pain: influences on morphine and metabolite concentration.
@en
Oral morphine in cancer pain: influences on morphine and metabolite concentration.
@nl
prefLabel
Oral morphine in cancer pain: influences on morphine and metabolite concentration.
@en
Oral morphine in cancer pain: influences on morphine and metabolite concentration.
@nl
P2093
P356
P1476
Oral morphine in cancer pain: influences on morphine and metabolite concentration.
@en
P2093
P304
P356
10.1038/CLPT.1990.145
P407
P577
1990-09-01T00:00:00Z